{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:34:35Z","timestamp":1783031675094,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma, accounting for a significant proportion of skin cancer-related deaths, has variable survival outcomes based on the stage at diagnosis and treatment efficacy. Traditional treatments, while effective, pose risks of scarring and systemic side effects. Laser therapy offers an emerging non-surgical alternative, with CO2 lasers particularly showing promise in palliative care.<\/jats:p><jats:p>A comprehensive search was conducted using PubMed, focusing on laser therapy for melanoma treatment. The search included studies on both stand-alone and adjunct laser therapies, with inclusion criteria requiring peer-reviewed articles detailing treatment outcomes for primary, recurrent, or metastatic melanoma.<\/jats:p><jats:p>The literature shows that laser therapy for melanoma falls into four major types when categorized by laser medium: solid-state, diode, pulse-dye, and gas (CO2). Data on solid-state lasers for melanoma are limited and their use remains controversial. However, one study with high-energy pulsed neodymium lasers reported a 5-year survival of 82.9% with minimal adverse effects for primary melanoma. CO2 laser therapy has been effective for palliative treatment, with one study showing 54.8% of patients with recurrent melanoma surviving 5.4 years post-ablation. For metastatic melanoma, numerous studies have shown that CO2 laser therapy can provide symptomatic relief and disease control. Combination therapies using lasers and immune-based therapies have demonstrated enhanced outcomes and immune activation, highlighting the potential of laser therapies in melanoma management.<\/jats:p><jats:p>While traditional treatments remain the standard for primary melanoma, laser therapies, particularly CO2 laser ablation, show substantial promise in palliative care for metastatic melanoma. Careful patient selection and assessment are crucial for achieving positive outcomes.<\/jats:p>","DOI":"10.1007\/s00403-024-03107-9","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T07:01:46Z","timestamp":1716620506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The palliative role of lasers in the treatment of melanoma"],"prefix":"10.1007","volume":"316","author":[{"given":"Yanci A.","family":"Algarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Pulumati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Jaalouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie C.","family":"Zeitouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"10400","key":"3107_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA (2023) Cutaneous melanoma. Lancet Lond Engl 402(10400):485\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(23)00821-8","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"3107_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ (2019) Current state of melanoma diagnosis and treatment. Cancer Biol Ther 20(11):1366\u20131379. https:\/\/doi.org\/10.1080\/15384047.2019.1640032","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"3107_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/medsci9040063","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A (2021) Epidemiology of Melanoma. Med Sci Basel Switz 9(4):63. https:\/\/doi.org\/10.3390\/medsci9040063","journal-title":"Med Sci Basel Switz"},{"issue":"1","key":"3107_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"3107_CR5","unstructured":"Sundararajan S, Thida AM, Yadlapati S, Koya S (2023) Metastatic Melanoma. In: StatPearls. StatPearls Publishing; Accessed November 1, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470358\/"},{"issue":"1","key":"3107_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40257-020-00562-8","volume":"22","author":"E Sharon","year":"2021","unstructured":"Sharon E, Snast I, Lapidoth M et al (2021) Laser treatment for Non-melanoma skin Cancer: a systematic review and Meta-analysis. Am J Clin Dermatol 22(1):25\u201338. https:\/\/doi.org\/10.1007\/s40257-020-00562-8","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"3107_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/lsm.10118","volume":"32","author":"HHL Chan","year":"2003","unstructured":"Chan HHL, Xiang L, Leung JCK, Tsang KWT, Lai KN (2003) In vitro study examining the effect of sub-lethal QS 755 nm lasers on the expression of p16INK4a on melanoma cell lines. Lasers Surg Med 32(2):88\u201393. https:\/\/doi.org\/10.1002\/lsm.10118","journal-title":"Lasers Surg Med"},{"issue":"4","key":"3107_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000246133","volume":"194","author":"D Kopera","year":"1997","unstructured":"Kopera D, Hohenleutner U, Stolz W, Landthaler M (1997) Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells. Dermatol Basel Switz 194(4):344\u2013350. https:\/\/doi.org\/10.1159\/000246133","journal-title":"Dermatol Basel Switz"},{"issue":"2","key":"3107_CR9","first-page":"389","volume":"15","author":"KG Moskalik","year":"2010","unstructured":"Moskalik KG, Kozlov AP, Demin EV (2010) High-energy neodymium laser radiation for the treatment of face cutaneous melanoma. J BUON off J Balk Union Oncol 15(2):389\u2013391","journal-title":"J BUON off J Balk Union Oncol"},{"issue":"7","key":"3107_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/bjs.4558","volume":"91","author":"SC Gibson","year":"2004","unstructured":"Gibson SC, Byrne DS, McKay AJ (2004) Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 91(7):893\u2013895. https:\/\/doi.org\/10.1002\/bjs.4558","journal-title":"Br J Surg"},{"issue":"3","key":"3107_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10103-008-0580-0","volume":"24","author":"N Kandamany","year":"2009","unstructured":"Kandamany N, Mahaffey P (2009) Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 24(3):411\u2013414. https:\/\/doi.org\/10.1007\/s10103-008-0580-0","journal-title":"Lasers Med Sci"},{"issue":"10","key":"3107_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/bjs.1800821016","volume":"82","author":"MK Lingam","year":"1995","unstructured":"Lingam MK, McKay AJ (1995) Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. Br J Surg 82(10):1346\u20131348. https:\/\/doi.org\/10.1002\/bjs.1800821016","journal-title":"Br J Surg"},{"issue":"1","key":"3107_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/DSS.0000000000000251","volume":"41","author":"JA van Jarwaarde","year":"2015","unstructured":"van Jarwaarde JA, Wessels R, Nieweg OE, Wouters MWJM, van der Hage JA (2015) CO2 laser treatment for regional cutaneous malignant melanoma metastases. Dermatol Surg off Publ Am Soc Dermatol Surg Al 41(1):78\u201382. https:\/\/doi.org\/10.1097\/DSS.0000000000000251","journal-title":"Dermatol Surg off Publ Am Soc Dermatol Surg Al"},{"issue":"1","key":"3107_CR14","doi-asserted-by":"publisher","first-page":"MMT14","DOI":"10.2217\/mmt-2018-0008","volume":"6","author":"OM Vrielink","year":"2019","unstructured":"Vrielink OM, Kruijff S, van Leeuwen BL, Roodenburg JL (2019) Application of CO2 laser evaporation in locally advanced melanoma. Melanoma Manag 6(1):MMT14. https:\/\/doi.org\/10.2217\/mmt-2018-0008","journal-title":"Melanoma Manag"},{"issue":"2","key":"3107_CR15","first-page":"173","volume":"19","author":"S Hill","year":"1993","unstructured":"Hill S, Thomas JM (1993) Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 19(2):173\u2013177","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"4","key":"3107_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/bjs.1800830425","volume":"83","author":"S Hill","year":"1996","unstructured":"Hill S, Thomas JM (1996) Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 83(4):509\u2013512. https:\/\/doi.org\/10.1002\/bjs.1800830425","journal-title":"Br J Surg"},{"issue":"1","key":"3107_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/14764172.2011.649761","volume":"14","author":"LKW Chan","year":"2012","unstructured":"Chan LKW, Quaba AA (2012) Improving the quality of life in melanoma: the role of the CO(2) laser. J Cosmet Laser Ther off Publ Eur Soc Laser Dermatol 14(1):43\u201347. https:\/\/doi.org\/10.3109\/14764172.2011.649761","journal-title":"J Cosmet Laser Ther off Publ Eur Soc Laser Dermatol"},{"issue":"5","key":"3107_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s0748-7983(97)93726-4","volume":"23","author":"LJ Strobbe","year":"1997","unstructured":"Strobbe LJ, Nieweg OE, Kroon BB (1997) Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 23(5):435\u2013438. https:\/\/doi.org\/10.1016\/s0748-7983(97)93726-4","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"3","key":"3107_CR19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3892\/ol.2016.5530","volume":"13","author":"DJ Chen","year":"2017","unstructured":"Chen DJ, Li XS, Zhao H et al (2017) Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: a clinical study. Oncol Lett 13(3):1425\u20131431. https:\/\/doi.org\/10.3892\/ol.2016.5530","journal-title":"Oncol Lett"},{"issue":"6","key":"3107_CR20","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/j.jaad.2009.12.028","volume":"62","author":"LA Kottschade","year":"2010","unstructured":"Kottschade LA, Weenig RH, Otley CC, McWilliams RR, Markovic SN (2010) The use of pulsed dye laser in the treatment of melanoma metastatic to the skin: a Mayo Clinic case series. J Am Acad Dermatol 62(6):e22\u201325. https:\/\/doi.org\/10.1016\/j.jaad.2009.12.028","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3107_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2133.2005.06307.x","volume":"152","author":"NC Zeitouni","year":"2005","unstructured":"Zeitouni NC, Dawson K, Cheney RT (2005) Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser. Br J Dermatol 152(2):376\u2013377. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06307.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"3107_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/jbio.201600271","volume":"10","author":"MF Naylor","year":"2017","unstructured":"Naylor MF, Zhou F, Geister BV, Nordquist RE, Li X, Chen WR (2017) Treatment of advanced melanoma with laser immunotherapy and ipilimumab. J Biophotonics 10(5):618\u2013622. https:\/\/doi.org\/10.1002\/jbio.201600271","journal-title":"J Biophotonics"},{"issue":"11","key":"3107_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.4161\/cbt.10.11.13434","volume":"10","author":"X Li","year":"2010","unstructured":"Li X, Naylor MF, Le H et al (2010) Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther 10(11):1081\u20131087. https:\/\/doi.org\/10.4161\/cbt.10.11.13434","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3107_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","volume":"43","author":"A Testori","year":"2017","unstructured":"Testori A, Ribero S, Bataille V (2017) Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(3):544\u2013560. https:\/\/doi.org\/10.1016\/j.ejso.2016.10.005","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"3","key":"3107_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/02656730701816402","volume":"24","author":"HJ Hoekstra","year":"2008","unstructured":"Hoekstra HJ (2008) The European approach to in-transit melanoma lesions. Int J Hyperth off J Eur Soc Hyperthermic Oncol North Am Hyperth Group 24(3):227\u2013237. https:\/\/doi.org\/10.1080\/02656730701816402","journal-title":"Int J Hyperth off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"issue":"6","key":"3107_CR26","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1245\/s10434-016-5103-9","volume":"23","author":"ASL Bagge","year":"2016","unstructured":"Bagge ASL, Ben-Shabat I, Belgrano V, Olofsson Bagge R (2016) Health-Related Quality of Life for patients who have In-Transit Melanoma Metastases Treated with isolated limb perfusion. Ann Surg Oncol 23(6):2062\u20132069. https:\/\/doi.org\/10.1245\/s10434-016-5103-9","journal-title":"Ann Surg Oncol"},{"key":"3107_CR27","unstructured":"Pathak S, Zito PM (2023) Clinical Guidelines for the Staging, Diagnosis, and Management of Cutaneous Malignant Melanoma. In: StatPearls. StatPearls Publishing; Accessed January 4, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572149\/"},{"key":"3107_CR28","unstructured":"National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology: cutaneous melanoma. Version 1.2023. National Comprehensive Cancer Network"},{"issue":"1","key":"3107_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/1346-8138.13484","volume":"44","author":"S Delker","year":"2017","unstructured":"Delker S, Livingstone E, Schimming T, Schadendorf D, Griewank KG (2017) Melanoma diagnosed in lesions previously treated by laser therapy. J Dermatol 44(1):23\u201328. https:\/\/doi.org\/10.1111\/1346-8138.13484","journal-title":"J Dermatol"},{"issue":"3","key":"3107_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1684\/ejd.2010.0933","volume":"20","author":"MC Zipser","year":"2010","unstructured":"Zipser MC, Mangana J, Oberholzer PA, French LE, Dummer R (2010) Melanoma after laser therapy of pigmented lesions\u2013circumstances and outcome. Eur J Dermatol EJD 20(3):334\u2013338. https:\/\/doi.org\/10.1684\/ejd.2010.0933","journal-title":"Eur J Dermatol EJD"},{"issue":"3","key":"3107_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1684\/ejd.2007.0167","volume":"17","author":"N Niiyama","year":"2007","unstructured":"Niiyama N, Niiyama S, Takasu H, Katsuoka K (2007) Progression of lentigo maligna into lentigo maligna melanoma following laser treatment. Eur J Dermatol EJD 17(3):252\u2013253. https:\/\/doi.org\/10.1684\/ejd.2007.0167","journal-title":"Eur J Dermatol EJD"},{"issue":"4","key":"3107_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1046\/j.1365-2133.2003.05591.x","volume":"149","author":"SL Woodrow","year":"2003","unstructured":"Woodrow SL, Burrows NP (2003) Malignant melanoma occurring at the periphery of a giant congenital naevus previously treated with laser therapy. Br J Dermatol 149(4):886\u2013888. https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05591.x","journal-title":"Br J Dermatol"},{"issue":"1","key":"3107_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1610-0387.2003.02002.x","volume":"1","author":"A B\u00f6er","year":"2003","unstructured":"B\u00f6er A, Wolter M, Kaufmann R (2003) [Pseudomelanoma following laser treatment or laser-treated melanoma?]. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 1(1):47\u201350. https:\/\/doi.org\/10.1046\/j.1610-0387.2003.02002.x","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"issue":"1","key":"3107_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/00015550510044154","volume":"86","author":"C Gottschaller","year":"2006","unstructured":"Gottschaller C, Hohenleutner U, Landthaler M (2006) Metastasis of a malignant melanoma 2 years after carbon dioxide laser treatment of a pigmented lesion: case report and review of the literature. Acta Derm Venereol 86(1):44\u201347. https:\/\/doi.org\/10.1080\/00015550510044154","journal-title":"Acta Derm Venereol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03107-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03107-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03107-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:33:32Z","timestamp":1719401612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03107-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03107-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors YAA, AP, and DJ, JN, and NCZ declare that they have NO affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"\u2022 iVeena Delivery Eye Drug Delivery systems (Bought with my own funds, Stock Shareholder (Individual stocks; diversified mutual funds do not need to be disclosed)).\u2022 Pfizer (Bought with my own funds, Stock Shareholder (Individual stocks; diversified mutual funds do not need to be disclosed)).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"KN has the following disclosures:"}}],"article-number":"244"}}